[52, 53] Our study provided strong evidence of the protective effect of SGLT2 inhibition on AF in the general population by using a set of robust genetic instruments of SGLT2 as the instrument variables and a large GWAS for AF. The gene discussed is SLC5A2; the disease is atrial fibrillation.